FALLS CHURCH, Va., Jan. 27 /PRNewswire/ -- FDAnews announced today its newest publication, Pharmaceutical Corporate Compliance Report, the only resource that provides insight into the full range of compliance risks. "Pharmaceutical manufacturers are under attack for more than just sales and marketing practices," says Cynthia Carter, president of FDAnews. "From drug pricing to patient privacy, from corporate accounting to research subject protection, more and more drug companies are facing costly and embarrassing litigation for what has been standard business practice." The pharmaceutical industry is coming under increased scrutiny on a host of non-FDA regulatory issues including: FTC's pledge to step up drug company antitrust investigations; the Accreditation Council for Continuing Education's restrictive new CME standards; state AG enforcement initiatives; the Sarbanes- Oxley; HIPAA privacy and Qui Tam actions. Published biweekly, each issue of Pharmaceutical Corporate Compliance Report goes beyond the news to answer critical compliance questions drug companies are asking, and provides guidelines for developing, monitoring and managing effective compliance programs. Benefit from Pharmaceutical Corporate Compliance Report's staff of regulatory and legislative reporters, as well as the insight of compliance experts including industry compliance and ethics officers, attorneys, consultants and government officials who specialize in the issues you're facing today ... and will face tomorrow. For a limited time, FDAnews is offering Pharmaceutical Corporate Compliance Report at a special pre-publication rate of $697, $100 off the regular $797 subscription rate. For subscription information, call toll-free (888) 838-5578, +1 (703) 538-7600 or visit http://www.fdanews.com/wbi/pccr/. * Premiere issue April 2003 Pharmaceutical Corporate Compliance Report is published by FDAnews, publishers of Drug Industry Daily, Washington Drug Letter, Part 11 Compliance Report, Generic Line, Devices & Diagnostics Letter and many other information services to help pharmaceutical, biotech and medical device executives meet legal, regulatory and business challenges.